Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?

Progress in Lipid Research

Volumn 51, Issue 4, 2012, Pages 314-324

  Otocka Kmiecik, Aneta ^a   Mikhailidis, Dimitri P ^b   Nicholls, Stephen J ^c   Davidson, Michael ^d   Rysz, Jacek ^a   Banach, MacIej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Dyslipidemia; High density cholesterol; Inflammation; Lipids; Therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANACETRAPIB; APOLIPOPROTEIN; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FERRIC ION; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYELOPEROXIDASE; NICOTINIC ACID; PEPTIDE DERIVATIVE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TORCETRAPIB;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATALYSIS; CHOLESTEROL TRANSPORT; CHRONIC INFLAMMATION; DISEASE COURSE; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW;

ANIMALS; APOLIPOPROTEINS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; PEROXIDASE; THIAZOLIDINEDIONES;

EID: 84861585543     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2012.03.003     Document Type: Review

References (129)

1. W.P. Castelli Cholesterol and lipids in the risk of coronary artery disease. The Framingham heart study Can J Cardiol 4 Suppl. A 1988 5A 10A
2. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, and J.D. Knoke High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
3. Huxley RR, Barzi F, Lam TH, For the Asia Pacific Cohort Studies Collaboration and the Obesity in Asia Collaboration, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the asia-pacific region. Circulation 2011 Oct 10. [Epub ahead of print].
4. P.W. Wilson High-density lipoprotein, low-density lipoprotein and coronary artery disease Am J Cardiol 66 1990 7A 10A
5. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA 285 2001 2486 2497
6. B.G. Brown, and X.Q. Zhao Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk Am J Cardiol 101 2008 58B 62B
7. W.P. Castelli, R.J. Garrison, P.W. Wilson, R.D. Abbott, S. Kalousdian, and W.B. Kannel Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study JAMA 256 1986 2835 2838
8. D.P. Mikhailidis, M. Elisaf, M. Rizzo, K. Berneis, B. Griffin, and A. Zambon "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary Curr Vasc Pharmacol 9 2011 531 532
9. D.P. Mikhailidis, M. Elisaf, and M. Rizzo "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses Curr Vasc Pharmacol 9 2011 533 571
10. M.J. Chapman, S. Goldstein, D. Lagrange, and P.M. Laplaud A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum J Lipid Res 22 1981 339 358
11. D.W. Anderson, A.V. Nichols, T.M. Forte, and F.T. Lindgren Particle distribution of human serum high density lipoproteins Biochim Biophys Acta 493 1977 55 68
12. B.F. Asztalos, C.H. Sloop, L. Wong, and P.S. Roheim Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations Biochim Biophys Acta 1169 1993 291 300
13. P. Duriez, and J.C. Fruchart High-density lipoprotein subclasses and apolipoprotein A-I Clin Chim Acta 286 1999 97 114
14. M.N. Nanjee, and E.A. Brinton Very small apolipoprotein A-I-containing particles from human plasma: isolation and quantification by high-performance size exclusion chromatography Clin Chem 46 2000 207 223
15. P.J. Barter The regulation and remodelling of HDL by plasma factors Atherosclerosis Suppl. 3 2002 39 47
16. A. Kontush, S. Chantepie, and M.J. Chapman Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress Arterioscler Thromb Vasc Biol 23 2003 1881 1888
17. N. Sakuma, M. Yoshikawa, T. Hibino, N. Ohte, T. Kamiya, and M. Kunimatsu HDL3 exerts a more powerful antiperoxidative and protective effect against peroxidative modification of LDL than HDL2 does J Nutr Sci Vitaminol 48 2002 278 282
18. M.E. Brousseau, G.P. Eberhart, J. Dupuis, B.F. Asztalos, A.L. Goldkamp, and E.J. Schaefer Freeman MW cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size J Lipid Res 41 2000 1125 1135
19. J.F. Oram The cholesterol mobilizing transporter ABCA1 as a new therapeutic target for cardiovascular disease Trends Cardiovasc Med 12 2002 170 175
20. Y. Zhang, I. Zanotti, M.P. Reilly, J.M. Glick, G.H. Rothblat, and D.J. Rader Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo Circulation 108 2003 661 663
21. A. Jonas Regulation of lecithin cholesterol acyltransferase activity Prog Lipid Res 37 1998 209 234
22. A. von Eckardstein, J.R. Nofer, and G. Assmann High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport Arterioscler Thromb Vasc Biol 21 2001 13 27
23. A. Agrawal, D.J. Hammond, and S.K. Singh Atherosclerosis-related functions of C-reactive protein Cardiovasc Hematol Disord Drug Targets 10 2010 235 240
24. P.J. Barter, S. Nichollas, K.A. Rye, G.M. Anantharamaiah, M. Navab, and A.M. Fogelman Antiinflammatory properties of HDL Circ Res 95 2004 764 772
25. C. Wadham, N. Albanese, J. Roberts, L. Wang, C.J. Bagley, and J.R. Gamble High-density lipoproteins neutralize C-reactive protein proinflammatory activity Circulation 109 2004 2116 2122
26. A. Soro-Paavonen, J. Westerbacka, C. Ehnholm, and M.R. Taskinen Metabolic syndrome aggravates the increased endothelial activation and lowgrade inflammation in subjects with familial low HDL Ann Med 38 2006 229 238
27. A.D. Tselepis, M.E. Tsoumani, K.I. Kalantzi, A.A. Dimitriou, C.C. Tellis, and I.A. Goudevenos Influence of HDL and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy J Thromb Haemost 9 12 2011 2371 2378
28. J.R. Nofer, M.F. Brodde, and B.E. Kehrel High-density lipoproteins, platelets and the pathogenesis of atherosclerosis Clin Exp Pharmacol Physiol 37 2010 726 735
29. W.A. Van Sickle, H.G. Wilcox, K.U. Malik, and A. Nasjletti High density lipoprotein-induced cardiac prostacyclin synthesis in vitro: relationship to cardiac arachidonate mobilization J Lipid Res 27 1986 517 522
30. C. Oslakovic, M.J. Krisinger, A. Andersson, M. Jauhiainen, C. Ehnholm, and B. Dahlbäck Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins J Biol Chem 284 2009 5896 5904
31. C. Mineo, H. Deguchi, J.H. Griffin, and P.W. Shaul Endothelial and antithrombotic actions of HDL Circ. Res. 98 2006 1352 1364
32. M. Aviram, M. Rosenblat, C.L. Bisgaier, R.S. Newton, S.L. Primo-Parmo, and B.N. La Du Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions J Clin Invest 101 1998 1581 1590
33. Y. Nagano, H. Arai, and T. Kita High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification Proc Natl Acad Sci USA 88 1991 6457 6461
34. M. Florentin, E.N. Liberopoulos, A.S. Wierzbicki, and D.P. Mikhailidis Multiple actions of high-density lipoprotein Curr Opin Cardiol 23 2008 370 378
35. E.A. Podrez Anti-oxidant properties of high-density lipoprotein and atherosclerosis Clin Exp Pharmacol Physiol 37 2010 719 725
36. M. Navab, S.Y. Hama, G.P. Hough, G. Subbanagounder, S.T. Reddy, and A.M. Fogelman A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids J Lipid Res 42 2001 1308 1317
37. M. Navab, S.Y. Hama, and G.M. Anantharamaiah Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3 J Lipid Res 41 2000 1495 1508
38. D.J. Gordon, and B.M. Rifkind High-density lipoproteins - the clinical implications of recent studies N Engl J Med 321 1989 1311 1316
39. J.J. Kastelein, S.I. van Leuven, and L. Burgess Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630
40. B.J. Ansell, M. Navab, and S. Hama N. et al. Inflammatory/ antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756
41. Van. Lenten Becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures J Clin Invest 96 1995 2758 2767
42. B.J. Van Lenten, A.C. Wagner, G.M. Anantharamaiah, D.W. Garber, M.C. Fishbein, and L. Adhikary Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide Circulation 106 2002 1127 1132
43. K.G. Lagos, T.D. Filippatos, V. Tsimihodimos, I.F. Gazi, C. Rizos, and A.D. Tselepis Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome Lipids 44 1 2009 9 16
44. E. Nobecourt, S. Jacqueminet, B. Hansel, S. Chantepie, A. Grimaldi, and M.J. Chapman Defective antioxidative activity of small, dense HDL particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycemia Diabetologia 48 2005 529 538
45. C. Morgantini, A. Natali, B. Boldrini, S. Imaizumi, M. Navab, and A.M. Fogelman Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes Diabetes 60 2011 2617 2623
46. A. Daugherty, J.L. Dunn, D.L. Rateri, and J.W. Heinecke Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. oxidation, is expressed in human atherosclerotic lesions J Clin Invest 94 1994 437 444
47. L. Zheng, B. Nukuna, and M.L. Brennan Apolipoprotein A-I is a selective target for myeloperoxidase catalyzed oxidation and functional impairment in subjects with cardiovascular disease J Clin Invest 114 2004 529 541
48. X. Fu, S.Y. Kassim, W.C. Parks, and J.W. Heinecke Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase J Biol Chem 276 2001 41279 41287
49. H.M. Abu-Soud, and S.L. Hazen Nitric oxide is a physiological substrate for mammalian peroxidases J Biol Chem 275 2000 37524 37532
50. L. Zheng, M. Settle, G. Brubaker, D. Schmitt, S.L. Hazen, and J.D. Smith Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages J Biol Chem 280 2005 38 47
51. S. Jayaraman, D.L. Gantz, and O. Gursky Effects of protein oxidation on the structure and stability of model discoidal high-density lipoproteins Biochemistry 47 2008 3875 3882
52. D. Kutter, P. Devaquet, G. Vanderstocken, J.M. Paulus, V. Marchal, and A. Gothot Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol 104 2000 10 15
53. R. Pecoits-Filho, P. Stenvinkel, A. Marchlewska, O. Heimburger, P. Bárány, and C.M. Hoff A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients Kidney Int 84 2003 172 176
54. R.M. Roman, P.V. Camargo, F.K. Borges, A.P. Rossini, and C.A. Polanczyk Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients Coron Artery Dis 21 2010 129 136
55. S. Baldus, C. Heeschen, T. Meinertz, A.M. Zeiher, J.P. Eiserich, and T. Munzel Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes Circulation 108 2003 1440 1445
56. W. Khovidhunkit, M.S. Kim, and R.A. Memon Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host J Lipid Res 45 2004 1169 1196
57. B. Lamarche, S. Rashid, and G.F. Lewis HDL metabolism in hypertriglyceridemic states: an overview Clin Chim Acta 286 1999 145 161
58. D.J. Greene, J.W. Skeggs, and R.E. Morton Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI) J Biol Chem 276 2001 4804 4811
59. W. Khovidhunkit, R.A. Memon, K.R. Feingold, and C. Grunfeld Infection and inflammation-induced proatherogenic changes of lipoproteins J Infect Dis 181 Suppl. 3 2000 S462 S472
60. S.P. Deakin, and R.W. James Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1 Clin Sci 107 2004 435 447
61. K.R. Feingold, R.A. Memon, A.H. Moser, and C. Grunfeld Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response Atherosclerosis 139 1998 307 315
62. B.J. Van Lenten, S.T. Reddy, M. Navab, and A.M. Fogelman Understanding changes in high density lipoproteins during the acute phase response Arterioscler Thromb Vasc Biol 26 2006 1687 1688
63. W. Jang, J. Shim, D.Y. Lee, P. Dutta, J.R. Kim, and K.H. Cho Rapid detection of dysfunctional high-density lipoproteins using isoelectric focusing-based microfluidic device to diagnose senescence-related disease Electrophoresis 32 2011 3415 3423
64. R.O. Ryan Nanobiotechnology applications of reconstituted high density lipoprotein J Nanobiotechnol 8 2010 28
65. L.E. Spieker, I. Sudano, D. Hurlimann, P.G. Lerch, M.G. Lang, and C. Binggeli High-density lipoprotein restores endothelial function in hypercholesterolemic men Circulation 105 2002 1399 1402
66. J.C. Tardif, J. Grégoire, P.L. L'Allier, R. Ibrahim, J. Lespérance, and T.M. Heinonen Effect of rHDL on atherosclerosis-safety and efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682
67. R.E. Moore, M.A. Kawashiri, K. Kitajima, A. Secreto, J.S. Millar, and D. Pratico Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor Arterioscler Thromb Vasc Biol 23 2003 1914 1920
68. A. Plump, C. Scott, and J. Breslow Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc Natl Acad Sci USA 91 1994 9607 9611
69. S. Ameli, A. Hultgardh-Nilsson, B. Cercek, P.K. Shah, J. Forrester, and H. Ageland Recombinant apolipoprotein A-1 Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits Circulation 90 1994 1935 1941
70. D. Li, S. Weng, B. Yang, D.S. Zander, T. Saldeen, and W.W. Nichols Inhibition of arterial thrombus formation by apoA-I Milano Arterioscler Thromb Vasc Biol 19 1999 378 383
71. L. Calabresi, C.R. Sirtori, R. Paoletti, and G. Franceshini Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular diseases Curr Atheroscler Rep 8 2006 163 167
72. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, P. Schoenhagen, C.J. Cooper, and M. Yasin Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
73. M. Navab, G.M. Anantharamaiah, S.T. Reddy, S. Hama, G. Hough, and V.R. Grijalva Apolipoprotein A-I mimetic peptides Arterioscler. Thromb. Vasc. Biol. 25 2005 1325 1331
74. G.M. Anantharamaiah, V.K. Mishra, D.W. Garber, G. Datta, S.P. Handattu, and M.N. Palgunachari Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides J Lipid Res 48 2007 1915 1923
75. M. Navab, G.M. Anantharamaiah, S.T. Reddy, B.J. Van Lenten, G.M. Buga, and A.M. Fogelman Peptide mimetics of apolipoproteins improve HDL function J Clin Lipidol 1 2007 142 147
76. L.T. Bloedon, R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, and B.J. DeGroot Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J Lipid Res 49 2008 1344 1352
77. M. Navab, G.M. Anantharamaiah, and S.T. Reddy Oral D-4F causes formation of pre-{beta} high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice Circulation 109 2004 3215 3220
78. A. Haber, A. Mahammed, B. Fuhrman, N. Volkova, R. Coleman, and T. Hayek Amphiphilic/bipolar metallocorroles that catalyze the decomposition of reactive oxygen and nitrogen species, rescue lipoproteins from oxidative damage, and attenuate atherosclerosis in mice Angew Chem Int Ed Engl 47 2008 7896 7900
79. A. Haber, M. Aviram, and Z. Gross Protecting the beneficial functionality of lipoproteins by 1-Fe, a corrole-based catalytic antioxidant Chem Sci 2 2011 295 302
80. W. Le Goff, and M. Guerin And Chapman MJ Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia Pharmacol Ther 101 2004 17 38
81. B.F. Asztalos, K.V. Horvath, K. Kajinami, C. Nartsupha, C.E. Cox, and M. Batista And Mabuchi H Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency J Lipid Res 45 2004 448 455
82. A. Kontush, E.C. de Faria, S. Chantepie, and M.J. Chapman A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity Atherosclerosis 182 2005 277 285
83. R.J. Bisoendial, G.K. Hovingh, K. El Harchaoui, J.H.M. Levels, S. Tsimikas, and K. Pu And stroes ESG consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia Arterioscler Thromb Vasc Biol 25 2005 e133 e134
84. M.E. Brousseau, M.R. Diffenderfer, and J.S. Millar Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies: apolipoprotein A-I metabolism, and fecal sterol excretion Arterioscler Thromb Vasc Biol 25 2005 1057 1064
85. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Digenio, and R.W. Clark Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
86. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, and M. Komajda ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
87. M. Vergeer, M.L. Bots, and S.I. van Leuven Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials Circulation 118 2008 2515 2522
88. S.J. Nicholls, D.M. Brennan, and K. Wolski Changes in levels of high density lipoprotein cholesterol predict the impact of torcetrapib on progression of coronary atherosclerosis: insights from ILLUSTRATE Circulation 116 suppl. 16 2007 2 127
89. D.J. Rader Illuminating HDL - is it still a viable therapeutic target? N Engl J Med 357 2007 2180 2183
90. T.F. Lüscher, S. Taddei, J.C. Kaski, J.W. Jukema, D. Kallend, and T. Münzel dal-VESSEL investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial Eur Heart J 33 2012 857 865
91. B. Zhang, P. Fan, E. Shimoji, H. Xu, K. Takeuchi, and C. Bian Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits Arterioscler Thromb Vasc Biol 24 2004 1910 1915
92. J. Kobayashi, H. Okamoto, M. Otabe, H. Bujo, and Y. Saito Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage Atherosclerosis 162 2002 131 135
93. Z.A. Fayad, V. Mani, and M. Woodward Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial Lancet 378 2011 1547 1559
94. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, and A.M. Gotto Determining the efficacy and tolerability investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
95. R.S. Rosenson Antiatherothrombotic effects of nicotinic acid Atherosclerosis 171 2003 87 96
96. M.J. Chapman, G. Assmann, J.C. Fruchart, J. Shepherd, and C. Sirtori Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European consensus panel on HDL-C Curr Med Res Opin 20 2004 1253 1268
97. T. Sakai, V.S. Kamanna, and M.L. Kashyap Niacin, but not gemfibrozil, selectively increases LPAI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol Arterioscler Thromb Vasc Biol 21 2001 73 79
98. T. Rubic, M. Trottmann, and R.L. Lorenz Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-blinding cassette A1 in monocytoid cells by niacin Biochem Pharmacol 67 2004 411 419
99. AIM-HIGH Investigators, W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
100. S.J. Nicholls Is niacin ineffective? Or did AIM-HIGH miss its target? Cleve Clin J Med 79 2012 38 43
101. J.C. Fruchart, and P. Duriez Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism Drugs Today (Barc) 42 2006 39 64
102. J.P. Despres, I. Lemieux, and S.J. Robins Role of fibric acid derivatives in the management of risk factors for coronary heart disease Drugs 64 2004 2177 2198
103. R.S. Birjmohun, B.A. Hutten, J.J. Kastelein, and E.S. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials J Am Coll Cardiol 45 2005 185 197
104. K. Ikewaki, J. Tohyama, Y. Nakata, T. Wakikawa, T. Kido, and S. Mochizuki Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study J Atheroscler Thromb 11 2004 278 285
105. B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebret, and I.P. Torra Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators Nature 393 6687 1998 790 793
106. V. Tsimihodimos, A. Kakafika, A.P. Tambaki, E. Bairaktari, M.J. Chapman, and M. Elisaf Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins J Lipid Res 44 2003 927 934
107. E.S. Istvan, and J. Deisenhofer Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 2001 1160 1164
108. M. Banach, D.P. Mikhailidis, S.E. Kjeldsen, and J. Rysz Time for new indications for statins? Med Sci Monit 15 2009 MS 1 MS5
109. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
110. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. airforce/texas coronary atherosclerosis prevention study JAMA 279 1998 1615 1622
111. M. Guerin, T.S. Lassel, W. Le Goff, M. Farnier, and M.J. Chapman Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles Arterioscler Thromb Vasc Biol 20 2000 189 197
112. S.S. Soedamah-Muthu, H.M. Colhoun, M.J. Thomason, D.J. Betteridge, P.N. Durrington, and G.A. Hitman The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease Atherosclerosis 167 2003 243 255
113. F.H. Rached, and H.D.L. Are Particles dysfunctional in Acute coronary syndrome patients with STEMI and low HDL-cholesterol levels: impact of statin? The 79th EAS congress 2011 Gothenburg Sweden 26-29
114. M. Harangi, I. Seres, Z. Varga, G. Emri, Z. Szilvassy, and G. Paragh Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage Eur J Clin Pharmacol 60 2004 685 691
115. B. Fuhrman, L. Koren, and N. Volkova Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes Atherosclerosis 164 2002 179 185
116. J. Rysz, W.S. Aronow, R.S. Stolarek, S. Hannam, D.P. Mikhailidis, and M. Banach Nephroprotective and clinical potential of statins in dialyzed patients Expert Opin Ther Targets 13 2009 541 550
117. A. Bielecka-Dabrowa, D.P. Mikhailidis, S. Hannam, W.S. Aronow, J. Rysz, and M. Banach Statins and dilated cardiomyopathy: do we have enough data? Expert Opin Investig Drugs 20 2011 315 323
118. B.J. Ansell, M. Navab, S. Hama, N. Kamranpour, G. Fonarow, and G. Hough Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756
119. S.J. Nicholls, E.M. Tuzcu, I. Sipahi, A.W. Grasso, P. Schoenhagen, and T. Hu Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 2007 499 508
120. N. Katsiki, D.P. Mikhailidis, and M. Banach Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels J Hypertens 29 2011 2493 2494
121. E.S. Nakou, T.D. Filippatos, D.N. Kiortsis, C.S. Derdemezis, A.D. Tselepis, and D.P. Mikhailidis The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia Expert Opin Pharmacother 9 2008 3151 3158
122. M.A. Deeg, J.B. Buse, and R.B. Goldberg Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia Diabetes Care 30 10 2007 2458 2464
123. J.G. Juárez-Rojas, A.X. Medina-Urrutia, E. Jorge-Galarza, N.A. Caracas-Portilla, R. Posadas-Sánchez, and G.C. Cardoso-Saldaña Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial Lupus 21 2012 27 35
124. S. Sam, S. Haffner, M.H. Davidson, R. D'Agostino Sr, A. Perez, and T. Mazzone Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes J Clin Endocrinol Metab 97 2012 E110 E114
125. M. Rizzo, J. Vekic, S. Koulouris, A. Zeljkovic, Z. Jelic-Ivanovic, and V. Spasojevic-Kalimanovska Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes Angiology 61 6 2010 584 590
126. A.P. Pandey, S. Bissonnette, S. Boukas, E. Rampakakis, and J.S. Sampalis Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial Arch Med Sci 7 2011 767 775
127. N. Katsiki, D.P. Mikhailidis, V.G. Athyros, A.I. Hatzitolios, A. Karagiannis, and M. Banach Are we getting to lipid targets in real life? Arch Med Sci 6 2010 639 641
128. A. Bielecka-Dabrowa, S. Hannam, J. Rysz, and M. Banach Malignancy-associated dyslipidemia Open Cardiovasc Med J 5 2011 35 40
129. L. Gordon, D. Ragoobirsingh, E. Morrison, D. McGrowder, E. Choo-Kang, and E. Martorell Dyslipidaemia in hypertensive obese type 2 diabetic patients in Jamaica Arch Med Sci 6 2010 701 708